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Although it is now well established that a substantial proportion of wild-living primates in sub-Saharan Africa harbor SIV, no study to date has
examined to what extent the various species are naturally infected. In this study, we first describe the development and validation of sensitive and
specific SIV antibody detection assays representing all major known primate lentiviral lineages on a panel of 207 sera from 11 different primate
species with known infection status. The newly developed assays were then used to determine SIV prevalence rates in nine primate species native
to Cameroon. Analysis of 722 sera revealed widely varying prevalence rates, ranging from an apparent absence of SIV infection in crested mona
(0/70), grey cheeked (0/36) and agile mangabeys (0/92), to prevalence rates of 3%, 4%, 11%, 27%, 39% and 52% for mustached (6/203), greater
spot-nosed (8/193), northern talapoin (3/26), mantled guereza (14/52), De Brazza’s (9/23) and mandrill (14/27) monkeys, respectively. The
epidemiology of naturally occurring SIV infections is thus more complex than previously appreciated and the various non-human primate hosts
seem to differ in their susceptibility to SIV infection. The newly developed assays should now permit to define with greater accuracy existing SIV
reservoirs and associated human zoonotic risk.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV; SIV; Prevalence; Non-human primates; CameroonIntroduction
Simian immunodeficiency viruses (SIVs) comprise a
diverse group of lentiviruses that infect a wide variety of
non-human primate species in sub-Saharan Africa (Bailes et al.,
2002; Peeters and Courgnaud, 2002). Although seemingly not
pathogenic for their natural hosts, these viruses have gained0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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46.
E-mail address: martine.peeters@mpl.ird.fr (M. Peeters).public health attention since two of them have given rise to the
human AIDS viruses, human immunodeficiency virus types 1
and 2 (HIV-1 and HIV-2). It is now well established that HIV-1
resulted from cross-species transmissions of SIVcpz naturally
infecting chimpanzees (Pan troglodytes troglodytes) in west
central Africa; similarly, HIV-2 resulted from multiple trans-
missions of SIVsmm infecting sooty mangabeys (Cercocebus
atys) in west Africa (Corbet et al., 2000; Damond et al., 2001;
Gao et al., 1992; Hahn et al., 2000; Yamaguchi et al., 2000). To
date, serological evidence of SIV infection has been reported in
36 different primate species and partial or full-length viral
sequences have been recovered from 29 of these (Bibollet-6) 174 – 189
www.e
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has revealed an extraordinary degree of genetic diversity, with
different SIVs varying by as much as 60% of their protein
sequences (Bibollet-Ruche et al., 2004); however, SIV
diversity is generally species specific, that is SIVs cluster as
monophyletic lineages according to their species of origin,
which has been used to classify them by adding a three-letter
code reflecting their common species name.
Although both SIVcpz and SIVsmm are known to have
crossed the species barrier to humans on multiple occasions
(Corbet et al., 2000; Damond et al., 2001; Gao et al., 1992,
1999; Yamaguchi et al., 2000), the transmission potential of
the other primate lentiviruses remains unknown. In a recent
survey of bushmeat markets in Cameroon, we found evidence
suggesting that a substantial proportion of wild-living
monkeys are SIV infected (Peeters et al., 2002). Among 788
monkeys, representing 16 different species, a considerable
fraction (17%) was found to harbor antibodies that cross-
reacted with HIV-1 and HIV-2 antigens in a confirmatory
(recombinant protein and synthetic peptide based) immunoas-
say (INNO-LIA, Innogenetics, Ghent, Belgium). PCR analysis
of a subset of these cross-reactive samples led to the discovery
of new SIV strains not previously known to infect primates.
This bushmeat market survey thus documented for the first
time that humans who hunt and butcher primates are routinely
exposed to a plethora of genetically divergent SIV strains.
However, the exact prevalence of SIV infection in the 16
species under study could not be determined because of the
unknown extent of antigenic cross-reactivity of the HIV-based
test.
Given the extraordinary degree of primate lentivirus
diversity, no assay based on a single HIV or SIV strain is
likely to be sufficiently cross-reactive to reliably detect
antibodies directed against all other strains. To develop SIV-
specific antibody detection tests, several groups have examined
linear or multiple antigenic peptides (MAPs) encompassing the
V3-loop region and/or the immunodominant gp41 ectodomain
of the SIV envelope glycoprotein as antibody capture antigens
(Masciotra et al., 2000; Ndongmo et al., 2004; Simon et al.,
2001). While these approaches have been useful in detecting
strain-specific antibodies in selected primate and human
reference sera, not all known SIV strains have thus far been
targeted for peptide design and their utility for diagnosing SIV
infection in wild primate populations representing different
species remains to be tested (Ndongmo et al., 2004; Masciotra
et al., 2000; Simon et al., 2001). Finally, confirmatory
immunoblot assays for SIVs other than SIVcpz/HIV-1 and
SIVsmm/HIV-2 have not been developed. Thus, sensitive and
specific diagnostic tools suitable for systematic and compre-
hensive surveys of SIV infection in wild primate populations
still need to be developed.
To begin to characterize the epidemiology of natural SIV
infections, we expressed the gp41 ectodomain of 11 different
SIV strains and used these recombinant proteins, along with
corresponding V3 loop peptides, as ELISA antigens to screen
722 primate sera for antibodies directed against SIVs from the
same (homologous) and other (heterologous) species. Theresults revealed a surprising array of seroprevalences, ranging
from the apparent absence of SIV in some species to high level
(50%) infection in others. Moreover, the overall number of SIV
rgp41 ELISA-positive sera was considerably lower than that of
INNO-LIA-positive sera, suggesting that for a subset of
species, INNO-LIA had overestimated existing infection rates.
These data thus indicate that not all naturally occurring SIV
infections are common and wide spread, and that strain-specific
screening and confirmatory assays will be required to
determine the true extent of SIV infection in wild-living
primate populations.
Results
Strain-specific ELISA-based assays for SIV antibody detection
To develop a comprehensive panel of SIV-specific serolo-
gical assays, we selected antigens from 13 different strains
which together represent all major known primate lentiviral
lineages (Bibollet-Ruche et al., 2004). For 11 of these, we
expressed the ectodomain of the transmembrane envelope
glycoprotein (Figs. 1A and B) which is known to be highly
immunogenic and has previously been used for SIV and HIV
antibody detection (Allain et al., 1987; Georges-Courbot et al.,
1998; Masciotra et al., 2000; Mauclere et al., 1997; Ndongmo
et al., 2004; Saah et al., 1987; Simon et al., 2001).
Recombinant proteins were generated as poly-histidine tagged
fusion proteins and purified by metal ion affinity chromatog-
raphy (Fig. 2). We also synthesized V3 loop peptides for 10
SIV strains, including SIVlho and SIVagm for which rgp41
proteins were not available (Fig. 1C; Table 1). Both rgp41
proteins and V3 loop peptides were evaluated as ELISA
antigens using a panel of well-characterized reference sera
from primates of known (PCR confirmed) infection status
(Table 2).
To determine the cutoff values for the various peptide and
rgp41 ELISAs, we examined the reactivity of sera from 144
uninfected monkeys (antibody and PCR negative) from 11
different species. For each test, the mean optical density (OD)
plus five standard deviations was selected as the cut-off value,
an approach deliberately intended to be conservative
(Crowther, 2001). Fig. 3 depicts the results of these studies,
with cut-off values indicated by red dots (vertical boxes with
error bars represent the 25th and 75th percentiles of the
negative serum reactivities for each antigen). The results
revealed an overall lower background with peptide compared
to rgp41 antigens.
The reactivity of the negative serum panel was then used to
determine assay specificities. As shown in Tables 3a and 3b,
none of the negative sera tested positive in the corresponding
(homologous) rgp41 ELISA, and this was also true for the
homologous peptide ELISAs except for one sooty mangabey
serum that reacted weakly with the cognate SIVsmm V3 loop
peptide. Thus, the overall specificity of homologous antibody
detection was 100% for the rgp41 ELISAs, and 99% for the
peptide ELISAs (Tables 3a and 3b). However, 3 of 144
negative sera reacted with low OD/cut-off ratios with
Fig. 1. (A) Schematic representation of the HIV/SIV transmembrane envelope glycoprotein (adapted from Desmezieres et al. (2005)). Amino acid residues included
in the respective bacterially expressed gp41 fragments are shown as closed circles, with heptad repeat HR-1 and HR-2 domains highlighted in red and blue,
respectively. Open circles represent rgp41 amino acid residues not present in the recombinant protein, including the fusion peptide (FP), the transmembrane domain
(TM) and the intra-cytoplasmic region (CY). (B) Alignment of recombinant SIVrgp41 ectodomain sequences. The HIV-1 HXB2 amino acid sequence is shown as a
reference, with the heptad repeat HR-1 and HR-2 domains underlined in red and blue, respectively. Amino acid residues conserved among all proteins are shown in
red. SIV gp41 proteins are subdivided into four different groups (indicated by brackets) according to the phylogenetic relationships of their full-length Env protein
sequences as shown in panel C (Bibollet-Ruche et al., 2004). Within groups, dots denote amino acid identity with the top sequence, while dashes were introduced to
optimize the alignment. The length of the SIVrgp41 protein fragment is indicated for each strain. Black and green doted lines indicate the position of peptides used in
previously reported ELISA assays as described in Ndongmo et al. (2004); Simon et al. (2001), respectively. (C) Phylogenetic relationship of primate lentiviruses
based on Env protein sequences (as determined by the neighbor joining algorithm) (Saitou and Nei, 1987). SIV strains used to design recombinant gp41 proteins and/
or V3 loop peptides are indicated.
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Fig. 2. Expression and purification of recombinant SIV gp41 proteins. The
various SIV gp41 ectodomains were expressed as poly-histidine tagged fusion
protein and purified by metal ion affinity chromatography. Purified aliquots of
SIVtal-rgp41 (lane 2), SIVdeb-rgp41 (lane 3) and SIVcol-rgp41 (lane 4) were
analyzed by SDS-PAGE electrophoresis, using a 4–20% linear gradient ready
gel (BioRad) and stained using Coomassie brilliant blue G250. Protein markers
of known molecular weight are shown in lane 1 (precision plus protein dual
color standards, BioRad). Protein purity was estimated by using the
ChemiDoctm XRS Image System (BioRad, Hercules, CA). All expressed
purified recombinant SIVrgp41 proteins were greater than 85% pure.
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with heterologous peptides (Tables 3a and 3b; 4a and 4b).
Although such reactivities could be indicative of cross-species
infection, all sera reacted only weakly (OD/cut-off ratios less
than 1.65) and in each case only with a single heterologous
antigen. Moreover, the same sera tested negative in the
corresponding V3 loop or rgp41 ELISAs, strongly suggestingTable 1
V3 peptide sequences representing different SIV lineages used in the ELISAs
SIV SIV lineage
SIVcpz-ant HIV-1/SIVcpz
SIVgsn-166 SIVgsn/mon/mus
SIVagm-consensus SIVagm
SIVsmm-consensus HIV-2/SIVsmm
SIVsyk SIVsyk
SIVrcm SIVrcm
SIVmnd-1 SIVmnd
SIVlho SIVlho/sun
SIVcol SIVcol
SIVdeb SIVdebunspecific reactivities. Thus, the overall specificity of homo-
logous and heterologous antibody detection was 98% for the
rgp41 ELISAs, and 95% for the peptide ELISAs.
To determine the sensitivity of the various rgp41 and
peptide ELISAs, a panel of positive reference sera from
primates with PCR documented SIV infection was analyzed.
As shown in Tables 3a and 3b, 62 of the 63 sera reacted
strongly with the species-specific SIV gp41 proteins, indicating
an overall sensitivity of 98%. The single false negative serum
was from a known infected talapoin monkey. Although non-
reactive in the homologous SIVtal rgp41 ELISA, this same
sample scored positive in three other heterologous rgp41
ELISAs (SIVdeb, SIVsmm and SIVsyk) (Table 4a). Thus,
taking both homologous and heterologous rgp41 reactivities
into account, all antibody-positive sera were correctly identi-
fied. This was not the case for the synthetic peptide ELISAs
(Table 3b). Overall, only 50 of 61 positive sera scored positive
in the homologous peptide assays (82%), and this sensitivity
did not improve when heterologous peptide reactivities were
considered (Table 4b). Thus, while exhibiting similar specifi-
cities, the various peptide ELISAs were less sensitive at
detecting homologous and heterologous antibodies than their
rgp41 protein counterparts.
Extent of antigenic cross-reactivity between different SIV
strains
To estimate how many strain-specific antibody detection
tests would ultimately be required for comprehensive field
testing, we examined the extent of antigenic cross-reactivity
between the various (rgp41 and peptide) ELISAs and sera
from different SIV-infected primate species. These data are
summarized in Tables 4a and 4b, and in Fig. 4. Overall, the
rgp41 ELISAs were considerably more cross-reactive than
their peptide counterparts. For example, the SIVmon rgp41
ELISA detected all SIVmus, SIVgsn, SIVcpz, SIVmnd-2 and
SIVsyk infections, and the SIVsmm rgp41 ELISA identified
all SIVdeb, SIVtal and SIVsyk infections (Table 4a). By
contrast, only SIVgsn and SIVcpz peptide ELISAs detected
heterologous antibodies in an appreciable number of species,
although most of these harbored closely related viruses (Table
4b; Fig. 1C); all other peptide ELISAs detected no, or only a
negligible fraction of heterologous antibodies (Table 4b).
Consistent with previous observations, these results indicateV3-sequence
NRTVRNLQIGPGMTFYNVEIEATGDTRKAFC
GNKTIRNLQIGAGMTFYSQVIVGGNTRKAYC
GNKTVLPVTIMAGLVFHSQKYNTLLRQAWC
GNKTVVPITLMSGLVFHSQPINKRPRQAWC
GNESIKNIQLAAGYFLPVIQGKLKTGRDAKRAFC
SNRTVKGISLATGVFISLRVEKRPKGAWC
GNRSVVSTPSATGLLFYHGLEPGKNLKKGMC
GNRSEVSTISSTGLLFYYGLEHGSRLRLAQC
GNSSHRNLNTANGAKFYYELIPYSKGIYGRC
GNKTYRAVHMATGLSFYTTFIPRLRIKRAHC
Table 2
Serum reference panel from SIV-infected and non-infected non human primate
species
Species Common name SIV SIV
pos (n)
SIV
neg (n)
Cercopithecus
neglectus
De Brazza monkey SIVdeb 6 3
Cercopithecus
cephus
Mustached monkey SIVmus 4 31
Cercopithecus
nictitans
Greater spot nosed
monkey
SIVgsn 6 47
Cercopithecus
mona
Mona monkey SIVmon 1 1
Cercopithecus
albogularis
Sykes monkey SIVsyk 14 35
Colobus guereza Mantled guereza SIVcol 9 9
Mandrillus sphinx Mandrill SIVmnd-2 7 4
Miopithecus
ogouensis
Northern talapoin SIVtal 2 6
Cercocebus atys Sooty mangabey SIVsmm 9 7
Cercocebus
torquatus
Red capped
mangabey
SIVrcm 2 0
Pan troglodytes Chimpanzee SIVcpz 3 1
Total 63 144
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specific and thus more suitable to distinguish between
different SIV infections than antibodies directed against the
gp41 ectodomain (Masciotra et al., 2000; Ndongmo et al.,
2004; Simon et al., 2001). Overall, the SIVdeb, SIVsmm,
SIVmon and SIVtal rgp41 ELISAs were the most cross-
reactive, detecting 80%, 74%, 72%, and 70% of all
heterologous SIV infections, respectively. By contrast, SIV-Fig. 3. Evaluation of recombinant protein (left panel) and synthetic peptide (right p
primates (n =144). Vertical boxes with error bars represent the 25th [x25] to 75th [x
each recombinant gp41 protein and peptide. The middle of the box represents the med
the lower and upper adjacent values. The lower adjacent value is defined as the sma
value is defined as the largest data point less than or equal to x75+1.5 IQR. Observ
open circles (Stata 7.0 software, Stata Corporation, College Station, Texas, USA). R
standard deviations (Crowther, 2001).mus and SIVcpz rgp41 ELISAs were the least cross-reactive,
identifying only about 30% of heterologous SIV infections.
On a species level, sera from infected Sykes’s monkeys
reacted with the most, while sera from infected guereza
colobus reacted with the least number of heterologous rgp41
proteins. Indeed, three sera from SIVcol-infected colobus
monkeys reacted only with the homologous rgp41 ELISA.
ELISA OD values were higher for homologous than heterol-
ogous reactivities (Fig. 4).
Although most rgp41 ELISAs were highly cross-reactive,
the extent and direction of this cross-reactivity was variable.
For example, the SIVdeb rgp41 ELISA identified all positive
mandrill, Sykes’s, talapoin, sooty mangabey and mustached
monkey sera, but the reverse was only true for the SIVsmm
rgp41 ELISA. SIVmnd2, SIVsyk, SIVtal and SIVmus rgp41
ELISAs identified only 2/6, 5/6, 4/6 and 0/6 of all positive De
Brazza’s monkey sera, respectively. Similarly, the SIVcol
rgp41 ELISA detected all positive mustached and mona
monkey sera, but only 2 of 6 positive greater spot nosed
monkey sera; the remaining 4 went undetected despite the
fact that greater spot nosed, mustached and mona monkeys all
harbor genetically very closely related viruses (Fig. 1C).
Finally, the SIVtal rgp41 ELISA identified only one positive
talapoin serum, but detected 43 of 61 antibody-positive sera
(70%) from other species. Thus, while strain-specific anti-
bodies frequently cross-react with gp41 proteins from SIVs
infecting other species, the magnitude and direction of this
cross-reactivity is unpredictable and does not always correlate
with the phylogenetic relatedness of the respective SIV
strains.anel) based ELISAs (crude OD values) using sera from uninfected non-human
75] percentiles (the so-called interquartile range, IQR) of seroreactivity ODs for
ian or 50th percentile of the data, and the lines emerging from the box extend to
llest data point greater than or equal to x251.5 IQR and the upper adjacent
ed points more extreme than the adjacent values are individually represented by
ed dots denote cut-off values calculated as the mean OD for each antigen plus 5
Table 3a
Sensitivity and specificity of the rgp41 SIV ELISA assays
Species SIV Homologous antibody detection Homologous and heterologous antibody detection
Npos/Ntested Sensitivity Npos/Ntested Specificity Npos/Ntested Sensitivity Npos/Ntested Specificity
C. neglectus SIVdeb 6/6 100.0% 0/3 100.0% 52/63 82.5% 0/144 100.0%
C. cephus SIVmus 4/4 100.0% 0/31 100.0% 23/63 36.5% 1/144 99.3%
C. nictitans SIVgsn 6/6 100.0% 0/47 100.0% 35/63 55.6% 0/144 100.0%
C. mona SIVmon 1/1 100.0% 0/1 100.0% 46/63 73.0% 1/144 99.3%
C. albogularis SIVsyk 14/14 100.0% 0/35 100.0% 41/63 65.1% 0/144 100.0%
C. guereza SIVcol 9/9 100.0% 0/9 100.0% 37/63 58.7% 0/144 100.0%
M. sphinx SIVmnd-2 7/7 100.0% 0/4 100.0% 33/63 52.4% 0/144 100.0%
M. ogouensis SIVtal 1/2 50.0% 0/6 100.0% 44/63 69.8% 1/144 99.3%
C. atys SIVsmm 9/9 100.0% 0/7 100.0% 49/63 77.8% 0/144 100.0%
C. torquatus SIVrcm 2/2 100.0% NT  28/63 44.4% 0/144 100.0%
P. t. troglodytes SIVcpz 3/3 100.0% 0/1 100.0% 21/63 33.3% 0/144 100.0%
Total 62/63 98.4%
(91.5–100.0)a
0/144 100.0%
(97.9–100.0)a
63/63 100.0%
(95.4–100.0)a
3/144 97.9%
(94.0–99.6)a
a 95% confidence intervals.
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Following assay validation, the newly developed ELISAs
were employed to determine the prevalence of SIV infection
in nine primate species native to Cameroon. Blood was
collected from 589 additional monkeys sampled at various
geographic sites, including bushmeat markets in and around
the capital city of Yaounde, logging concessions in southeast-
ern Cameroon, and villages in southwestern Cameroon. Thus,
samples were collected over a wide range of locations
representing different home ranges throughout southern
Cameroon. All sera were subjected to homologous and
heterologous rgp41 ELISA testing, while V3 peptide ELISAs
were conducted in only selected cases. All sera were also
screened by INNO-LIA to compare SIV strain specific with
HIV cross-reactive antibody responses. Together with negative
and positive reference sera from wild populations in Camer-
oon, INNO-LIA and rgp41 ELISA results were generated for
a total of 722 primates.Table 3b
Sensitivity and specificity of the V3-peptide SIV ELISA assays
Species SIV Homologous antibody detectiona
Npos/N tested Sensitivity Npos/Ntested Sp
C. neglectus SIVdeb 2/6 33.3% 0/3 10
C. cephus SIVgsn 4/4 100.0% 0/31 10
C. nictitans SIVgsn 5/6 83.3% 0/47 10
C. mona SIVgsn 1/1 100.0% 0/1 10
C. albogularis SIVsyk 14/14 100.0% 0/35 10
C. guereza SIVcol 8/9 88.9% 0/9 10
M. sphinx SIVmnd-2 7/7 100.0% 0/4 10
C. atys SIVsmm 6/9 66.7% 1/7 8
C. torquatus SIVrcm 1/2 50.0% NT –
P. troglodytes SIVcpz 2/3 66.7% 0/1 10
– SIVlhoc NT – NT –
– SIVagmc NT – NT –
Total 50/61 82.0%
(70.0–90.6)d
1/138 9
(96
a Samples from Northern talapoins (M. ogouensis) were excluded for the homolo
b All 207 sera from the reference panel were tested with all peptides.
c SIVlho and SIVagm were only validated for heterologous antibody detection du
d 95% confidence intervals.Table 5 summarizes the proportion of SIV rgp41 ELISA-
positive sera for members of six primate species for which an
infecting SIV strain has been molecularly characterized (Bibol-
let-Ruche et al., 2004; Courgnaud et al., 2001, 2002; Souquiere
et al., 2001) (F. Liegeois and M. Peeters, unpublished data).
The results indicate a surprising range of naturally occurring
SIV prevalences. Mandrills exhibited the highest infection rate,
with over half of all animals harboring SIVmnd2-specific
antibodies. De Brazza’s and guereza colobus monkeys revealed
intermediate seroprevalences, with 39% and 27% harboring
strain-specific antibodies, respectively. By contrast, many fewer
SIV seropositive talapoin (11%), greater spot nosed (3%) and
mustached monkeys (4%) were identified, despite large
numbers of available sera for the latter two species. All sera
were tested using the entire panel of rgp41 ELISAs, with
homologous assay results confirmed by heterologous assay
results. For example, two talapoin monkeys initially misidenti-
fied as negative by the homologous SIVtal rgp41 ELISA scored
positive in three heterologous rgp41 ELISAs (see below).Homologous and heterologous antibody detectionb
ecificity Npos/Ntested Sensitivity Npos/Ntested Specificity
0.0% 2/63 3.2% 1/144 99.3%
0.0%
0.0%
)
23/63 36.5%
)
1/144 99.3%
0.0%
0.0% 16/63 25.4% 0/144 100.0%
0.0% 8/63 12.7% 2/144 98.6%
0.0% 8/63 12.7% 0/144 100.0%
5.7% 6/63 9.5% 1/144 99.3%
3/63 4.8% 0/144 100.0%
0.0% 14/63 22.2% 1/144 99.3%
1/63 1.6% 1/144 99.3%
3/63 4.8% 0/144 100.0%
9.3%
.0–100.0)d
51/63 81.0%
(69.1–89.8)d
7/144 95.1%
(90.2–98.0)d
gous detection due to absence of SIVtal peptide.
e to absence of reference sera for the corresponding SIV infected primates.
Table 4a
Crossreactivity of SIV lineage-specific rgp41 ELISAs with sera from different primate species
SIV-positive and -negative reference sera from different primate species (left panel) have been tested with the 11 different rgp41 ELISAs (right panel). Homologous
Elisa’s are highlighted by a frame.
a nt, not tested.
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specific antibodies, we next examined which of the SIV
ELISA-positive sera also reacted with HIV-1 and HIV-2
proteins in the INNO-LIA assay and which exhibited
discordant results. This analysis identified widely varying
results depending on the species analyzed. For De Brazza’s
monkeys, both the SIVdeb rgp41 ELISA and the INNO-LIA
identified the same number of antibody-positive sera, indi-
cating 100% concordance for the two tests. For mandrills, 14
of 27 sera were SIVmnd-2 rgp41 ELISA-positive, and 15 of
27 sera were INNO-LIA-positive. PCR analysis of the one
discordant sample failed to detect SIVmnd-2 sequences,
suggesting absence of infection. Thus, with the exception of
one potentially unspecific INNO-LIA result, both tests yielded
comparable results. However, this was not the case for
guereza colobus monkeys. Only 8 of 14 SIVcol ELISA-
positive sera were also INNO-LIA-positive. Two of the
discordant sera were positive in the SIVcol V3 peptide
ELISA, and two others were confirmed by PCR amplification
of virus-specific sequences to be derived from SIVcol-
infected monkeys (not shown). Thus, for guereza colobus,
INNO-LIA reactivity clearly underestimated the true SIVcol
infection rate. The opposite was observed for northerntalapoin: only 1 of 26 sera tested SIVtal rgp41 ELISA-
positive, while 3 were INNO-LIA-positive. These same 3 sera
were also positive in heterologous SIVdeb, SIVsmm and
SIVsyk ELISAs, and all 3 were confirmed by PCR to be
derived from SIVtal-infected talapoin monkeys (Peeters et al.,
2002), (F. Liegeois and M. Peeters, unpublished data). Thus,
for northern talapoins, the INNO-LIA was more reliable than
the lineage-specific rgp41 ELISA for detecting SIVtal
infections.
By far, the most striking differences were observed for
greater spot nosed and mustached monkeys. For mustached
monkeys, only 6 of 203 sera were SIVmus rgp41 ELISA-
positive, compared to 77 sera that were INNO-LIA-positive.
Similarly, for greater spot nosed monkeys, only 8 of 193 sera
were SIVgsn rgp41 ELISA-positive, compared to 33 that were
INNO-LIA-positive, although all ELISA-positive sera were
also INNO-LIA-positive. Further analysis indicated that all
SIVgsn and SIVmus ELISA-positive sera also reacted with
heterologous SIV rgp41 proteins (Table 5) and that the great
majority was PCR-positive. By contrast, none of the discordant
INNO-LIA positives reacted with the rgp41 proteins from SIVs
infecting other species and none of a subset that was tested was
PCR positive.
Table 4b
Crossreactivity of SIV lineage-specific V3 peptide ELISA assays with sera from different primate species
SIV-positive and -negative reference sera from different primate species (left panel) have been tested with the 10 different V3- ELISAs (right panel). Homologous
Elisa’s are highlighted by a frame.
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To examine whether INNO-LIA positive but SIV ELISA
negative greater spot nosed and mustached monkeys lacked V3
loop and gp41 antibodies but harbored antibodies directed against
other envelope and/or core protein epitopes, we developed a
Western blot assay that utilized SIVgsn Env containing pseudo-
virions as immunoblot antigens. To generate these pseudovirions,
we first modified the codon usage of the SIVgsn env sequence to
resemble that of highly expressed human genes. Codon usage
optimized genes are known to express large quantities of
envelope glycoproteins, which are efficiently incorporated into
virus particles when expressed in trans (Andre et al., 1998; Gao
et al., 2003, 2005). The codon optimized SIVgsn env (gp160)
gene was then cotransfected with an env-minus HIV-1
backbone vector (HIV-1DenvSG3) (Wei et al., 2003), which
resulted in the production of SIVgsn Env containing pseudo-
virions. These were purified by centrifugation through a
sucrose cushion, analyzed for p24 Gag content, and used as
antigens on Western blot strips (100 ng of p24 per strip).
Fig. 5 depicts the Western blot profiles of three different
groups of sera: (i) greater spot nosed and mustached monkey
sera that were both SIV ELISA and INNO-LIA positive (left
panel); (ii) greater spot nosed and mustached monkey sera that
were INNO-LIA positive, but SIV ELISA negative (middlepanel); (iii) greater spot nosed monkey sera that were both SIV
ELISA and INNO-LIA negative (right panel). This analysis
identified SIV-specific antibodies only in sera that were also
SIV rgp41 ELISA positive: three greater spot nosed and three
mustached monkey sera reacted strongly with the exterior
portion (gp120) as well as the uncleaved gp160 precursor of
the SIVgsn envelope glycoprotein (codon usage optimized
envelope glycoproteins are only incompletely processed due to
saturation of cellular proteases; (Andre et al., 1998;Gao et al.,
2003, 2005)). Four of these same sera also recognized the
transmembrane envelope glycoprotein (gp41) and three cross-
reacted with the HIV-1 p24 Gag core protein. By contrast, all
other sera including five that exhibited strong INNO-LIA
reactivities with HIV-1 gp120 (S1079), gp41 (S43, S1267) and
p17 Gag proteins (S1287, S1285) (not shown), failed to react
with SIVgsn and HIV-1 proteins in the immunoblot assay.
Thus, the discordant INNO-LIA positives represented unspe-
cific reactivities.
Survey of primate species suspected to harbor SIV
Finally, we used the newly developed rgp41 ELISA to
screen sera from 92 agile mangabeys (Cercocebus agilis), 70
crested mona monkeys (Cercopithecus pogonias) and 36 gray-
cheeked mangabeys (Lophocebus albigena) for cross-reactive
Fig. 4. ELISA cross-reactivity pattern of sera from primates with PCR confirmed SIV infection status. Crude OD values are shown on the x axis for eleven different rgp41 ELISA tests. Sera from different primate
species are color-coded on the y axis. The cut-off for each test is indicated by a black horizontal line. For each ELISA, homologous antibody responses are shown in boxes.
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Table 5
SIV prevalence rates in wild primate populations in Cameroon
Species SIV strain HIV-1/2 INNO-LIA SIV rgp41 ELISA SIV prevalencea
(95% CI)
Npos/N tested Homologous
antibody detection
Npos/Ntested
Heterologous
antibody detection
Npos/N tested
Cercopithecus neglectus SIVdeb 9/23 9/23 9/23 39.1% (19.7–61.5)
Mandrillus sphinx SIVmnd-2 15/27 14/27 13/27 51.8% (31.9–71.3)
Colobus guereza SIVcol 8/52 14/52 8/52 26.9% (15.6–41.0)
Miopithecus ogouensis SIVtal 3/26 1/26 3/26b 11.5% (2.4–30.2)
Cercopithecus cephus SIVmus 77/203 6/203 6/203 2.9% (1.1–6.3)
Cercopithecus nictitans SIVgsn 33/193 8/193 8/193 4.1% (1.8–8.0)
Cercopithecus pogonias – c 19/70 NT (1)/70d 0%e (0.0–4.2)
Cercocebus agilis SIVagif 27/92 NT (1)/92d 0%e (0.0–3.2)
Lophocebus albigena – c 20/36 NT 0/36 0% (0.0–8.0)
a SIV prevalence rates were calculated using the combined homologous and heterologous antibody reactivities as determined by the various SIV rgp41 ELISAs.
b Two M. ogouensis samples were identified as antibody positive by heterologous SIV rgp41 ELISAs and both were confirmed to be derived from SIVtal infected
animals by PCR and sequence analysis.
c SIV infection has not yet been confirmed by amplification of SIV sequences.
d The single observed reactivities were most likely unspecific (see text for details).
e Confidence limits were calculated assuming zero positives among the sera tested.
f SIVrcm like partial pol sequences have been amplified from 2 captive agile mangabeys (see text for details).
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observed to react with HIV-1 and HIV-2 antigens, suggesting
they might harbor as yet unidentified SIV strains (Peeters et al.,
2002). Moreover, SIVrcm-like viruses were identified in two
captive agile mangabeys by PCR amplification of subgenomic
integrase sequences (E. Nerrienet, C. Apetrei, Y. Foupoua-
pouognigni, B. Ling, A. Luckay, L Chakrabarti, A. Ayouba,
and P. Marx, Abstr. 14th Int. AIDS Conf., abstr. TuPeA4405,
2002). We thus examined whether our panel of strain-specific
assays could uncover new SIV infections.Fig. 5. SIVgsn-specific Western immunoblot. The Western blot reactivities of greater
SIV PCR status as well as reactivity in SIVgsn and SIVmus rgp41 ELISA and INNO
shown. SIV-specific antibodies are detected only in sera that are both rgp41 ELISA
content; each strip contains 100 ng of p24 Gag protein. The positions of the SIVgsn g
Gag proteins p55, p24, and p17, are shown on the left. Lane 1 depicts reactivitiesConsistent with previous results, we found 66 of the 198
sera to be INNO-LIA positive. However, using the entire set of
rgp41 antigens, ELISA reactivity was only observed for two of
the 198 sera. One from an agile mangabey scored positive in
the SIVcol rgp41 ELISA, and the other from a crested mona
reacted weakly in the SIVsyk rgp41 ELISA. In both instances,
ELISA reactivities were limited to a single SIV rgp41 antigen,
and all attempts to amplify SIV sequences from these two
samples remained negative. Similarly, only 7 of the 198 sera
scored weakly positive in the V3 peptide ELISAs. Again, nonespot nosed (C. nictitans) and mustached (C. cephus) monkey sera (grouped by
-LIA assays, respectively) with SIVgsn Env containing HIV-1 pseudovirions are
and INNO-LIA positive. Pseudovirions were quantified by HIV-1 p24 antigen
p160, gp120, and gp41 envelope glycoproteins, along with the HIV-1 backbone
of a positive SIVcpz control (purified SIVcpzUS-specific IgG, 1 Ag/ml).
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none was PCR positive. Finally, none of the 66 INNO-LIA-
positive sera reacted with any of the SIV rgp41 ELISAs, and
none contained amplifiable sequences. Taken together, the SIV-
specific antibody detection assays failed to identify evidence of
SIV infection in the crested mona, agile and grey-cheeked
mangabey monkeys under study.
Discussion
Although it is now well established that a substantial
proportion of wild-living primates in sub-Saharan Africa
harbor SIV, no study to date has examined to what extent the
various species are naturally infected, whether some species are
the source of infection of others, and whether the viruses
currently recognized represent the totality of SIV infection in
nature. In this study, we describe the development and
validation of a comprehensive panel of SIV-specific antibody
detection tests and their use for SIV prevalence determinations
in nine primate species. The results revealed an unexpectedly
wide range of prevalence rates, with high levels of SIV
infection in some species and rare or no infection in others.
These data indicate that the epidemiology of naturally
occurring SIV infections is more complex than previously
appreciated and that the various non-human primate hosts
differ in their susceptibility to SIV infection.
Assay development and screening strategies
Synthetic peptides have been used in the past to detect HIV-
and SIV-specific antibodies in human and primate sera
(Ayouba et al., 2000, 2001; Masciotra et al., 2000; Mauclere
et al., 1997; Ndongmo et al., 2004; Simon et al., 2001).
However, peptides cover only very short epitopes and are
frequently not particularly sensitive as capture antigens unless
their coating efficiency is increased by chemical modification.
Moreover, antibodies directed against epitopes that differ in
only few amino acids might not be detected. To generate a
more robust set of antibody detection assays, we developed
ELISA strategies that utilized both peptides and recombinant
proteins as antibody capture antigens. For peptide design, we
selected the V3 region of the SIVenvelope because this domain
is known to elicit antibodies that are suitable for distinguishing
different SIV infections (Ndongmo et al., 2004; Simon et al.,
2001). For the protein component, we expressed the entire
ectodomain of the SIV transmembrane envelope domain
because this region is highly immunogenic and comprises
both linear and conformational epitopes due to partial refolding
(Barin et al., 1985; Weissenhorn et al., 1997; Xu et al., 1991).
The sensitivity and specificity of the newly devised assays
was determined using a comprehensive panel of well-charac-
terized reference sera. These analyses showed that all but one
of the rgp41 ELISAs detected homologous antibodies with
100% sensitivity and 100% specificity (Table 3a, 3b).
Moreover, most of the rgp41 ELISAs were quite cross-reactive
and thus provided corroborating evidence for homologous
antibody results, although the extent and direction of cross-reactivity varied based on the particular test and primate
species analyzed. The V3 loop peptide ELISAs were less
sensitive, but capable of discriminating between the different
SIV lineages. This panel of rgp41 and V3 peptide-based
ELISAs thus represents a comprehensive and versatile set of
SIV antibody screening assays.
Although the combination of SIVmon, SIVsmm and SIVcol
rgp41 ELISAs was sufficient to correctly identify all SIV
infections in the control panel, the number of positive reference
sera for each of the 11 primate species is still rather limited
(Table 2). Thus, future serological surveys of primate
population should employ the entire panel of rgp41 ELISAs,
especially for species suspected but not yet confirmed to harbor
SIV. Based on current data, we would expect true positives to
react with both homologous and heterologous rgp41 proteins as
well as with selected V3 loop peptides, especially if the latter
are modified to increase their sensitivity (Masciotra et al.,
2000; Ndongmo et al., 2004, Simon et al., 2001). As additional
SIV infections are identified and confirmed, it should be
possible to identify patterns of seroreactivity that are highly
predictive of infection, even in the absence of PCR confirma-
tion. In this context, it will be important to improve the
sensitivity of the current SIVtal rgp41 ELISA by expressing
and testing additional SIVtal rgp41 ectodomains and by
examining the genetic and antigenic diversity of the gp41
region among different SIVtal strains. Finally, inclusion of
recombinant SIVlho, SIVmnd-1 and SIVagm gp41 proteins
would ensure representation of all currently known SIV
lineages in the rgp41 ELISA screening panel.
HIV cross-reactivity as a predictor of SIV infection
All major SIV lineages known to date were initially
discovered because their primate hosts had antibodies that
cross-reacted with HIV-1 and/or HIV-2 antigens (Beer et al.,
1999; Bibollet-Ruche et al., 1997, 2004; Courgnaud et al.,
2001, 2003a, 2003b; Emau et al., 1991; Gao et al., 1999;
Georges-Courbot et al., 1998; Ohta et al., 1988; Osterhaus et
al., 1999; Peeters et al., 2002; Souquiere et al., 2001; Takehisa
et al., 2001). Since commercially available HIV screening
assays contain only a limited number of antigens, most SIV
studies have used Western blot type tests to screen for cross-
reactive antibodies. One of these, the INNO-LIA HIV
Confirmation test, has proven particularly useful in identifying
genetically divergent SIV strains. This test, which contains
recombinant HIV-1 and HIV-2 proteins and synthetic peptides
coated as discrete lines on a nylon strip, correctly identified 7
of the 13 currently known major SIV lineages (Bibollet-Ruche
et al., 2004; Courgnaud et al., 2001, 2002, 2003a, 2003b;
Peeters et al., 2002). Given this performance record, we
examined to what extent the INNO-LIA was also useful in
determining SIV prevalence rates in different primate species.
To determine the extent of INNO-LIA cross-reactivity, we
compared the relative proportions of INNO-LIA and SIV
ELISA-positive sera among the 722 primates analyzed. The
results revealed marked differences, depending on which
species was analyzed. For De Brazza’s monkeys, mandrills,
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and INNO-LIA tests performed at comparable levels, with very
similar numbers of SIV-infected monkeys correctly identified
(Table 5) (F. Bibollet-Ruche and B. H. Hahn, unpublished data).
For guereza colobus, INNO-LIA failed to identify 40% of
infected animals, but this was not unexpected given the extent
of genetic divergence of SIVcol from other SIVs in the envelope
region (Fig. 1C) and the low level of antigenic cross-reactivity
generally observed for positive guereza colobus sera (Table 4a)
(Ndongmo et al., 2004). However, the markedly discordant
results for greater spot nosed and mustached monkey sera came
as a surprise (Table 5). To exclude the possibility that infected
members of these two species lacked antibodies to the particular
ELISA antigens used, we tested a subset for reactivity with
SIVgsn Env containing HIV-1 pseudovirions (Fig. 5). This
analysis failed to detect SIV-specific antibodies in ELISA
negative sera, while SIVgsn envelope as well as the HIV-1 p24
Gag-reactive antibodies were readily identified in ELISA-
positive sera (Fig. 5). Moreover, none of the discordant
INNO-LIA-positive sera were PCR positive or reacted with
heterologous rgp41 antigens. Based on these data, we conclude
that the bulk of the observed INNO-LIA reactivities for greater
spot nosed and mustached monkeys are unspecific, and that the
same appears to be true for crested mona, agile and grey-
cheeked mangabeys (Table 5). It remains to be determined
whether the unspecific reactivities are directed against HIV
gene products or contaminating proteins in the INNO-LIA test.
Regardless of the outcome, it is clear that the INNO-LIA has
overestimated SIV prevalence rates in a number of different
primate species, and that HIV antigen-based assays cannot be
used to measure SIV prevalences in primate populations or
identify SIV infections in humans.
Widely varying prevalence rates in naturally infected primate
species
The great majority of primate species known to harbor a
primate lentivirus exhibit high levels of SIV infection. The
most extensively studied species, sooty mangabeys and African
green monkeys, exhibit prevalence rates that frequently exceed
50% in adult animals, and this has been documented both in
captivity and in the wild (Apetrei et al., 2005; Bibollet-Ruche
et al., 1997; Jolly et al., 1996; Phillips-Conroy et al., 1994).
High levels of SIV infection have also been identified in wild-
living mandrills, De Brazza’s and Sykes’s monkeys, although
relatively fewer animals have been characterized (Bibollet-
Ruche et al., 2004; Ellis et al., 2004; Souquiere et al., 2001;
Takehisa et al., 2001). Based on these results, it is now
generally assumed that all natural SIV infections are common
and widespread. Our finding of only 3% and 4% SIV infection
rates in mustached and greater spot nosed monkeys, respec-
tively, indicates that this assumption is not correct.
The reasons for varying SIV infection rates in different
primate species are not known, but are likely due to a
combination of viral, host and/or environmental factors. For
example, SIVgsn and SIVmus could represent SIVs that were
acquired relatively more recently and are thus not yet fullyadapted for efficient replication and spread in their new hosts. In
this case, the low prevalence would be due to intrinsic viral
properties. Alternatively, behavioral differences could some-
how limit the extent of virus exposure of greater spot nosed and
mustached monkeys relative to other species. However, it is
known that SIVgsn and SIVmus are transmitted, albeit
infrequently, among members of their respective primate
species because their sequences form species-specific clusters
in phylogenetic trees (Courgnaud et al., 2002, 2003a). In
general, primates were sampled at many different sites
throughout southern Cameroon and the few SIVgsn and
SIVmus antibody positive samples that were identified, were
derived from different geographic regions in Cameroon,
excluding sampling bias as the reason for the different
prevalence rates. Thus, while intrinsic viral properties or
primate behavior may play a role, host genetic factors are likely
the most important determinant of SIV transmission and
persistence in wild primate populations. A number of intrinsic
host defense mechanisms have recently been described (Bien-
iasz, 2004; Goff, 2004; Sheehy et al., 2002; Stremlau et al.,
2004), and such restriction factors could greatly influence the
relative susceptibility of primates to SIVs from their own as
well as other species. Deciphering these host factors and their
mechanisms of action will be important not only to understand
the epidemiology and natural history of the various SIVs, but
also to gauge their potential to cross-infect humans.
Finally, we used the newly developed antibody detection
assays to screen members of three primate species, i.e., crested
mona, agile and grey-cheeked mangabeys, which have been
suspected but not yet confirmed to be naturally infected with
SIV. Although a relative large number of sera scored INNO-LIA
positive (see above), no evidence of infection was found using
the SIV-specific assays. This result is particularly puzzling since
two of 20 captive agile mangabeys have previously been
reported to harbor SIVrcm-like viruses as determined by PCR
amplification of a subgenomic (integrase) sequence (E. Nerrie-
net, C. Apetrei, Y. Foupouapouognigni, B. Ling, A. Luckay, L
Chakrabarti, A. Ayouba, and P. Marx, Abstr. 14th Int. AIDS
Conf., abstr. TuPeA4405, 2002). Our ELISA panel included
both recombinant SIVrcm gp41 protein and V3 peptides; yet,
none of the 92 agile mangabey sera reacted with these antigens,
suggesting the absence of SIVrcm Env-reactive antibodies. It is
possible that SIVagi is a recombinant containing SIVrcm-like
sequences in its 5V half and the sequences from a highly
divergent SIV strain in its 3V half. Alternatively, the prevalence
of SIVagi in agile mangabeys may be exceedingly low.
Additional studies are required to address these possibilities
and to determine whether crested mona, agile and grey-cheeked
mangabeys harbor divergent SIV(s) that are not detected by the
current strain-specific assays.
Testing humans for SIV infection
Given the magnitude of existing SIV reservoirs, studies are
needed to determine whether transmission of simian lentiviruses
other than SIVcpz and SIVsmm have occurred in regions where
SIV infection of non-human primates is most prevalent. In this
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ing a wide range of naturally occurring SIV infections in
primates. These same assays should be applicable to screening
human risk groups that might constitute carriers of such
infections, such as individuals who are frequently exposed to
blood or bodily secretions of infected monkeys. In this context, it
is important to note that we have explored both screening and
confirmatory antibody detection strategies. Specifically, we
show that a codon usage optimized SIVgsn env gene can be
used to generate pseudovirions which carry a significant amount
of the SIVgsn envelope glycoprotein on their surface (Fig. 5).
Although the SIVgsn Env containing pseudovirions did not
mediate viral entry into CD4- and CCR5-positive human (JC53-
BL) cells (not shown), they were readily produced and purified,
and represented suitable Western blot immunogens (Fig. 5).
Identical strategies can be used to generate SIV/HIV pseudovir-
ions for all other naturally occurring SIV strains. In the absence
of replication competent isolates which are unavailable for most
SIV strains, this is the best strategy yet to document the presence
of specific envelope (gp160, gp120 and gp41) antibodies in SIV
rgp41 ELISA-reactive sera. Documentation of such antibodies
in human sera would be highly suggestive of SIV infection even
in the absence of PCR amplifiable viral sequences.
All SIV gp41 expression plasmids and the codon usage
optimized SIVgsn env gene have been submitted to the National
Institute of Health Research and Reagent Program, Bethesda,
MD and are thus available to investigators interested in the
epidemiology and natural history of natural SIV infections.
Materials and methods
Expression and purification of recombinant gp41 (rgp41)
proteins from different SIV strains
A gene segment spanning the ectodomain of the transmem-
brane (gp41) envelope domain (Fig. 1A) corresponding to amino
acids 31–168 of the HIV-1/HXB2 gp41 protein (GenBank
Accession number K03455) was amplified from molecular
clones of SIVcpzTAN1 (AF447763), SIVsmmCI2 (unpub-
lished), SIVrcmGAB1 (AF382829), SIVgsn99CM166 (AF46
8659), SIVmon99CMCML1 (AY340701), SIVmus01CM1085
(AY340700), SIVmnd2-14CG (AF328295), SIVdebCM40
(AY523865), SIVtal00CM266 (unpublished), SIVsykKE51
(AY523867), and SIVcolCGU1 (AF301156) (Fig. 1B), and
cloned into the bacterial expression vector pET-21d (Novagen,
Madison, MI) in-frame with a C-terminal hexahistidine
(6xHIS) tag. BL21-CodonPlus competent E. coli (Stratagene,
La Jolla, CA) were transformed with the respective pET-
SIVgp41 expression plasmids and grown overnight from a
single clone. Aliquots of these cultures were then used to
inoculate large-scale expression cultures. Expression of the
6xHIS-tagged SIV gp41 proteins was induced by adding
isopropyl-h-d-thiogalactopyranoside (IPTG) (Fisher Scientific,
Pittsburgh, PA) to the cultures (final concentration 1 mM) at an
optical density (OD) of 0.6–0.8. After an additional incubation
for 4 h at 37 -C, bacteria were harvested by low speed centri-
fugation at 4 -C, resuspended in 50 ml of phosphate-bufferedsaline (PBS, pH 7.2), disrupted by sonication and treated with
rLysozyme (Novagen, Madison, MI) for 20 min at room
temperature to release inclusion bodies (IB). These were then
concentrated by centrifugation, treated with Benzonase Nucle-
ase (90 U/ml) for 4 h at room temperature to digest bacterial
nucleic acids, washed three times with B-Per II bacterial pro-
tein extraction reagent (1:20) (Pierce, Rockford, IL), and solu-
bilized in 50 ml of denaturing buffer (PBS containing 8M urea
and 0.1% SDS). After pelleting debris, lysate supernatant was
passed through a column containing Ni-NTA Superflow resin
(Qiagen, Valencia, CA). The 6xHIS-tagged gp41 proteins were
subsequently eluted from the column with PBS containing
0.5M imidazole, 0.1% SDS, 8M urea and dialyzed against PBS
containing decreasing concentration of urea (4M, 2M and no
urea) and SDS (0.05%, 0.025% and 0.01%). Protein concen-
tration was determined using a bicinchoninic acid (BCA) pro-
tein assay reagent kit (Pierce, Rockford, CA), and the relative
purity of 6xHIS-tagged rgp41 proteins was examined by SDS-
PAGE electrophoresis, using 4–20% linear gradient ready gels
(BioRad, Hercules, CA). Proteins were visualized by Coomas-
sie brilliant blue G250 staining (Fig. 2) and their purity was
estimated by using the ChemiDoc XRS Image System
(BioRad, Hercules, CA). All expressed purified recombinant
SIVrgp41 proteins were greater than 85% pure (Fig. 2).
Synthetic (V3 loop) peptides
Synthetic peptides corresponding to the V3 loop region of
the extracellular envelope domain of ten different SIV strains
or lineages were purchased from Neosystems (Strasbourg,
France). Table 1 depicts the sequences of the different peptides
and their corresponding SIV strains. Because the V3 amino
acid sequences of SIVgsn, SIVmus and SIVmon were virtually
identical (Courgnaud et al., 2003a), only the SIVgsn V3 loop
peptide was synthesized. Similarly, the SIVmnd-2 V3 peptide
was used as a representative of both SIVmnd-1 and SIVmnd-2
strains which are monophyletic in the envelope gene (Fig. 1C).
Finally, consensus V3 loop sequences were synthesized for
SIVagm and SIVsmm lineages (Table 1).
Recombinant gp41 ELISA
ELISA plates (Corning, Corning, N.Y.) were coated (100 Al/
well) with recombinant gp41 (rgp41) protein (1 Ag/ml of total
protein in PBS, pH 7.2) and incubated at 4 -C overnight. Plates
were blocked using StabilCoat Immunoassay Stabilizer (Sur-
Modics, Eden Prairie, MN) (100 Al/well) for 1 h at room
temperature, dried at 37 -C for 2 h, and stored in a desiccator
until use. To test primate sera for the presence of SIV-specific
antibodies, plates were incubated with blocking buffer (PBS
containing 0.5% Tween-20, 5% non-fat dry milk) for 1 h at 37
-C, and washed with PBST (PBS with 0.1% Tween-20). Serum
or plasma samples were diluted 1:100 in blocking buffer, added
to each well (100 Al), incubated for 1 h at 37 -C, and washed
with PBST. Goat-anti-human IgG-HRP (Southern Biotech,
Birmingham, AL) was diluted 1:20,000 in blocking buffer,
added to each well (100 Al), and incubated for 1 h at 37 -C.
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benzidine (TMB) Solution (Sigma, St. Louis, MO) was added
and incubated for 20 min at room temperature. The reaction
was stopped by adding 100 Al of 1N sulfuric acid, and OD
values were measured at 450 nm against a reference
wavelength of 630 nm in EX-800 ELISA reader (BIO-TEK
Instruments, Inc., Winooski, VT).
Synthetic peptide ELISA
Polyvinylmicrotiter plates were coated with 0.25 Ag per well
of each peptide in a 0.05M bicarbonate buffer, pH 9.6, by
incubation at 37 -C for 20 h. After washing with phosphate-
buffer saline (PBS) containing 0.5% Tween 20, unoccupied sites
were blocked with PBS containing 5% fetal calf serum, for 2 h at
37 -C followed by washing with PBS-Tween. Sera were diluted
1:100 in a hypertonic PBS solution (0.01M sodium phosphate
buffer, pH 7.4, containing 0.75M NaCl, 10% fetal calf serum,
and 0.5% Tween 20). After incubation for 30 min at room
temperature, plates were washed and incubated with perox-
idase-conjugated goat anti-human IgG for 30 min at room
temperature. After washing, the reaction was developed with
hydrogen peroxide-o-phenylendiamine for 15 min at room
temperature in the dark. Reactions were terminated by adding
2N H2SO4, and optical densities (OD) were read at 492 nm.
Data analysis
Cut-off values for each peptide and rgp41 ELISA were
determined by calculating the mean optical densities (ODs) for
all antibody negative reference sera plus 5 standard deviations
(Crowther, 2001). A sample with an OD/cut-off ratio of equal
and/or greater than 1was scored positive, and a OD/cut-off value
of less than 1 was scored negative. For each peptide and rgp41
antigen, the sensitivity and specificity of detecting antibodies to
the homologous virus were calculated. Sensitivity was calculat-
ed as the number of ELISA-reactive samples divided by the total
number of SIV antibody-positive samples, multiplied by 100.
Specificity was calculated as the number of ELISA negative
samples, divided by the total number of SIV antibody negative
samples, multiplied by 100. Confidence limits were determined
given the assumption of binomial sampling (Stata 7.0 software,
Stata Corporation, College Station, TX, USA).
Reference sera from primates of known infection status
A panel of well-characterized reference sera was selected
from 207 primates in whom SIV infection was either confirmed
or excluded by PCR amplification of viral sequences from
peripheral blood mononuclear cell DNA (Table 2). The majority
of these sera were chosen from the previous bushmeat survey
(Peeters et al., 2002) and included sera from (infected/
uninfected) De Brazza’s (5/3), mustached (4/31), greater spot
nosed (6/47), mona (1/1), mandrill (7/4), mantled guereza (8/9)
and northern talapoin (2/6) monkeys. Additional sera from two
infected red capped mangabeys, one De Brazza’s monkey and
one guereza colobus were identified more recently. Referencesera were also obtained from captive chimpanzees (3/1), captive
sooty mangabeys (9/7) and wild-living Sykes’s monkeys (14/
35). The latter were collected from Lowland Sykes’ monkeys
(C. a. kibonotensis) in southern Kenya (close to Mombasa) and
Highland Sykes’s monkeys (C. a. kolbi) in central Kenya (in
the vicinity of Nairobi), which were trapped by investigators
of the Institute of Primate Research after obtaining approval
by the Kenya Wildlife Service. Following blood drawing, all
animals were released back into the wild. Blood samples were
first screened for HIV-1/HIV-2 cross-reactive antibodies and
subsequently subjected to PCR analysis using two sets of
virus-specific primers targeting pol and gp41 genes (F.
Bibollet-Ruche and B. H. Hahn, unpublished data).
Sera from primate bushmeat and pet monkeys
For prevalence determinations, 589 additional primates
were studied from geographically diverse sites throughout
southern Cameroon, including bushmeat markets in and
around the capital city of Yaounde, logging concessions in
southeastern Cameroon and villages in southwestern Camer-
oon. 265 of these were selected from the previous bushmeat
survey (Peeters et al., 2002), while an additional 324 were
obtained more recently. The selection criterion for all sera was
that they were available in sufficient quantities for multiple
serological analyses. As described previously, blood was
collected from primate bushmeat by cardiac puncture and
from pet monkeys by venipuncture after tranquilizing the
animals with ketamine (Peeters et al., 2002); all samples were
obtained with approval from the Cameroonian Ministry of
Environment and Forestry. Plasma and cells were separated on
site by Ficoll gradient centrifugation. All samples were
screened for HIV-1 and HIV-2 cross-reactive antibodies using
the INNO-LIA HIV Confirmatory assay (Innogenetics, Gent,
Belgium); however, PCR analysis was not performed to
confirm their respective infection status.
Codon usage optimization of the SIVgsn env gene
The codon usage of the SIVgsn99CM166 env sequence
(AF468659) was inspected and transcribed manually to that of
highly expressed human genes as described (Andre et al., 1998;
Gao et al., 2003). A Kozak sequence (GCCGCCGCC) was
added immediately prior to the first methionine codon (ATG)
and the modified sequence was subdivided into three non-
overlapping fragments, each of which was bounded by unique
restriction enzyme sites to facilitate cloning following gene
synthesis (fragment A: 1–873nt, XbaI–BspHI; fragment B:
866–1834nt, BspHI–SbfI; fragment C: 1827–2667nt, SbfI–
BamHI). None of these sequence modifications resulted in
changes of the SIVgsn encoded Env glycoprotein sequence.
The three fragments were purchased from a commercial vendor
(DNA 2.0, Menlo Park, CA), sequence confirmed upon receipt,
concatenated and cloned into the eukaryotic expression vector
pCMV/R (kindly provided by Dr. Gary Nabel). The codon
usage optimized CMV/R-SIVgsn env gene sequence is
available under GenBank accession number AY995800.
A.F. Aghokeng et al. / Virology 345 (2006) 174–189188SIVgsn-specific Western immunoblot
293T cells were co-transfected in 100 mm dishes (n =20)
with the codon usage optimized SIVgsn env gene (pCMV/R-
SIVgsnEnv; 10 Ag) and an env-minus HIV-1 backbone vector
(pSG3DEnv; 30 Ag) (Decker et al., 2005; Wei et al., 2003) to
generate HIV-1 pseudovirions containing the SIVgsn envelope
glycoprotein (Effectene Transfection Reagent, Qiagen, Valen-
cia, CA). Forty-eight hours post transfection, culture super-
natants were harvested, passed through 0.22 Am filter (Millipore
Express Plus Membrane filter; Millipore Corp., Bedford, MA),
and ultracentrifuged twice through a 20% sucrose cushion
(23,500g; 2 h). Pseudovirion pellets were resuspended in 500
Al PBS and quantified by determining their HIV-1 p24 antigen
content (Beckman Coulter, Fullerton, CA). Pseudovirions were
lysed in Reducing Sample Buffer (Pierce, Rockford, IL) and run
on a 4–15% linear gradient gel (BioRad, Hercules, CA).
Following electrophoresis, proteins were transferred to poly-
vinylidene difluoride (PVDF) membranes (BioRad, Hercules,
CA), incubated with StabilCoat Immunoassay Stabilizer (Sur-
Modics, Eden Prairie, MN) for 1 h at room temperature, and
dried. Individually cut membrane strips (4 mm width) were first
incubated with blocking buffer (5% nonfat dry milk, 3% fetal
bovine sera, 0.5% Tween-20 in PBS) for 1 h at room
temperature, and then reacted over night at 4 -C with sera from
greater spot-nosed and mustached monkeys (diluted 1:2,000 in
PBS) which had been pre-incubated with 293T cell lysates (1
mg total protein per ml of serum dilution) at room temperature
for 1 h to remove unspecific reactivities to cell derived antigens.
Protein-bound antibody was probed with goat-anti-human IgG-
HRP for 1 h at room temperature (1: 2,000; Southern Biotech,
Birmingham, AL) and developed using an enhanced chemilu-
minescence (ECL) detection system (Amersham Pharmacia
Biotech, Piscataway, NJ) on Hyperfilm-ECL.
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